



Advances in Therapy of Acute Myeloid Leukemia

Guest Editor:

Dr. Justyna Rybka

Department of Hematology,
Blood Neoplasms and Bone
Marrow Transplantation Wrocław
Medical University, Pasteur 4
Street, 50-367 Wrocław, Poland

Deadline for manuscript
submissions:

closed (15 March 2024)

Message from the Guest Editor

In recent years, new targeted therapies have developed in AML. These agents target various cellular processes: signaling pathways, DNA methylation, or chromatin remodeling. The new therapies include FLT3 inhibitors, IDH inhibitors, and Bcl-2 inhibitors. Each of these new therapies has different pharmacological profiles, adverse effects, and levels of effectiveness. A solid knowledge of the molecular basis of AML allows for the conscious application of new therapies. However, there is a large group of AML patients for whom molecular and genetic factors are unknown. Relapsed patients are particularly classified as being at significant risk. It is thus necessary to search for new molecular, genetic, and immunological factors that can play a prognostic role and become the target of new AML therapies in the future.

This Special Issue will be dedicated to new prognostic factors, and new therapies used in AML. Suitable topics include, but are not limited to: acute myeloid leukemia; new prognostic factors in acute myeloid leukemia; potential targeted therapies; pathogenesis of acute myeloid leukemia.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI